Published in

Oxford University Press, Clinical Infectious Diseases, 1(75), p. e888-e891, 2021

DOI: 10.1093/cid/ciab938

Links

Tools

Export citation

Search in Google Scholar

A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Journal article published in 2021 by Brian Grunau ORCID, Michael Asamoah-Boaheng, Pascal M. Lavoie, Mohammad Ehsanul Karim, Tracy L. Kirkham, Paul A. Demers, Vilte Barakauskas, Ana Citlali Marquez, Agatha N. Jassem, Sheila F. O’Brien, Steven J. Drews, Scott Haig, Sheldon Cheskes, David M. Goldfarb
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract The optimal dosing interval for severe acute respiratory syndrome coronavirus 2 vaccines remains controversial. In this prospective study, we compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short (17–28 days) vs long (42–49 days) interval. We found that a long dosing interval resulted in higher spike, receptor binding domain, and spike N terminal domain antibody concentrations.